A Clinical Study to Evaluate Safety and Immunologic Response of COMBIG-DC, in Patients With Metastatic Kidney Cancer

NCT01525017 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Renal Cell Carcinoma

Interventions

BIOLOGICAL: Combig-DC (allogeneic dendritic cells) Cancer Vaccine

Sponsor

Mendus